Most recent update: Tuesday, April 7, 2020 - 09:55

Bariatric News - Cookies & privacy policy

You are here

hypoglycaemia

Dasiglucagon effective in preventing post-gastric bypass hypoglycaemia

Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has announced positive topline results from a Phase 2 clinical trial using mini-doses of dasiglucagon in individuals who have undergone gastric bypass bariatric surgery.

XOMA 358 data shows desired mechanism-of-action

XOMA Corporation has announced that preliminary data from its ongoing XOMA 358 Phase 2 studies in patients with severe hypoglycaemia due to congenital hyperinsulinism (CHI) and post-bariatric surgery (PBS), has showed a reduction in the duration and number of hypoglycaemic episodes with increasing dose.

Positive Exendin (9-39) results for post-op hypoglycaemia patients

Positive results of a study evaluating subcutaneously administered exendin (9-39) in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycaemia) known as post-bariatric hypoglycaemia (PBH), have been presented by Stanford researchers at the American Diabetes Association 2016 annual meeting in New Orleans.

Weight gain, hypoglycaemia and the banded-bypass

Dr Rudolf Steffen is a bariatric and metabolic surgeon at the Hirslanden Klinik Beau-Site in Bern, Switzerland, one of the leading centres in the country for bariatric and metabolic surgery. Since 2003, he has performed more than 3,000 banded bypass operations and has recently utilised the MiniMizer Ring (Bariatric Solutions) as part of his procedure. Bariatric News talked to Professor Steffen to discuss the reasons why patients experience weight regain, the benefits of the banded-bypass and the advantages of the MiniMizer Ring.

Post-gastric hypoglycaemia study treats first patient

The first patient has been dosed in a Phase 2 study to evaluate subcutaneously administered exendin (9-39) in patients who experience dangerously low blood glucose levels (hypoglycaemia) after undergoing gastric bypass surgery. Exendin (9-39) is a 31-amino acid peptide, which selectively targets and blocks glucagon like peptide-1 (GLP-1) receptors, normalising insulin secretion by the pancreas, and thereby reducing hypoglycaemia.

Conservative approach for post-bypass hypoglycaemia

Patients presenting with hypoglycaemia following a gastric bypass can be treat effectively with a conservative approach which avoids expensive and unnecessary invasive studies, according to a case study (‘‘Conservative management in persistent hypoglycaemia: a cost effective option’, abstract No. 409) presented at the American Association of Clinical Endocrinologists’ annual meeting in Las Vegas.

IGF-1 testing could prevent hypoglycaemia

Testing for insulin-like growth factor 1 (IGF-1) could help to prevent postprandial hypoglycaemia following bariatric surgery, according to paper published by researchers from the Medical University Vienna, Vienna, Austria. The study was published online in the journal PlosOne.

Islet cell function contributes to hypoglycaemia post-surgery

Altered islet cell function and reduced insulin clearance contribute to excessive post-meal insulin response in patients experiencing hypoglycaemia following gastric bypass surgery, according to researchers from the University of Cincinnati (UC).

Hormone causes hypoglycaemia after bypass surgery

Blocking the action of one of the gut hormones can correct post-meal hypoglycaemia in gastric bypass patients, according to researchers at the University of Cincinnati (UC). The study, published the journal Gastroenterology, is part of an ongoing effort by UC researchers to better understand glucose metabolism after weight-loss surgery.

Does insulin sensitivity cause hypoglycaemia?

There appear to be distinct differences in whole body insulin sensitivity and insulin secretion among patients experiencing post-RYGB hypoglycaemia and this could explain the inconsistent clinical response to current medical and surgical treatments, according to research presented at ENDO2013, the annual meeting of the Endocrine Society, in San Francisco.

Subscribe to RSS - hypoglycaemia